L Veronica Lee
L Veronica Lee
Anticoagulant therapy for acute coronary syndromes is becoming more complex as newer agents are added to unfractionated heparin and warfarin. The anticoagulants used in current clinical practice are low molecular weight heparins, direct thr...
Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias [0.03%]
Ranolazine：心肌缺血、心肌功能不全和心律失常治疗的新方法
Peter H Stone
Peter H Stone
Ranolazine, which was approved by the US Food and Drug Administration in January 2006, provides a mechanism of action to treat ischemia that has not hitherto been available. Ranolazine is effective in reducing manifestations of ischemia and...
Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk [0.03%]
环氧化酶-2抑制剂、非甾体抗炎药与心血管风险的关系
Orly Vardeny,Scott D Solomon
Orly Vardeny
Cyclooxygenase-2 (cox-2) inhibitors, also known as coxibs, were introduced with the promise that they would provide pain relief similar to that of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) but would be better tolerated with ...
Prakash C Deedwania,Usman Javed
Prakash C Deedwania
This article reviews the results from several recent reports describing the safety and efficacy of statin therapy in the setting of heart failure. It additionally discusses the ongoing controversy regarding the lipid paradox and possible me...
Samuel Unzek,Gary S Francis
Samuel Unzek
Despite innovative medications and devices, heart failure (HF) continues to be the leading cause for admission to hospitals in the United States in patients older than 65 years. Many trials have succeeded in improving survival and many have...
Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? [0.03%]
胆固醇酯转移蛋白(CETP)抑制剂：托塞曲匹之后的前景如何？
Hemanth Neeli,Daniel J Rader
Hemanth Neeli
Despite tremendous progress made in the management of CHD, a significant number of fatal and nonfatal CHD events still occur, which leads researchers to target other modifiable risk factors for CHD including low HDL-c (high density lipoprot...
Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering? [0.03%]
肾素抑制剂：肾脏保护的新药还是更佳的降压药？
Eduardo Pimenta,Suzanne Oparil
Eduardo Pimenta
Aliskiren, the first in a new class of orally effective direct renin inhibitors (DRIs) was recently approved for the treatment of hypertension. In this review, we discuss the history of the development of DRIs and available data regarding t...
Usman Javed,Prakash C Deedwania
Usman Javed
The identification of patients at high risk for cardiovascular events is imperative in the reduction of cardiovascular mortality and morbidity. Although coronary artery disease, peripheral arterial disease, cerebrovascular disease, hyperten...
JoAnne M Foody
JoAnne M Foody
Michael H Crawford
Michael H Crawford